Latest news
29 July 2020
Cancer Research UK, University of Southampton and Touchlight Genetics Partner to develop head and neck cancer vaccine
Hampton, London, Southampton, UK – 29 July 2020 Cancer Research UK, the University of Southampton and Touchlight Genetics, a London based biotechnology company, today (Wednesday) announce a new clinical development partnership to progress a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC). HNSCC is the … Continued
18 June 2020
Touchlight to develop biobatteries with potential to address limitations of portable power supply
Hampton, UK – 18 June 2020 – Supported by the Office of Naval Research Global (ONR Global) and the Defense Science and Technology Laboratory (DSTL), Touchlight, a biotechnology company focused on the discovery and development of DNA-based genetic medicines, is working together with the Minteer Lab, University of Utah, to develop a DNA-enabled biobattery that could … Continued
5 June 2020
Touchlights’s chairman to help lead UK COVID-19 vaccine effort
Dr. Clive Dix appointed as Deputy Head of the UK’s Vaccine Taskforce Hampton, UK – 5 June 2020 – Touchlight, a biotechnology company focused on the discovery and development of DNA-based genetic medicines, today commented on the news that its Chairman, Dr. Clive Dix, has been appointed Deputy Chair of the UK’s Vaccine Taskforce. In this … Continued
27 April 2020
Touchlight appoints Dr. Helen Horton as Chief Research Officer
Former J&J Senior Scientific Director and immunology expert joins at a pivotal time Touchlight driving its dbDNA technology towards clinical development in therapeutic and prophylactic vaccines Hampton, UK – 27 April 2020 – Touchlight, a biotechnology company focused on the discovery and development of DNA-based genetic medicines, today announces the appointment of Dr. Helen Horton as … Continued